USRE49893EActiveUtility

[1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds

91
Assignee: BRISTOL MYERS SQUIBB COPriority: Jun 29, 2016Filed: Jan 25, 2022Granted: Apr 2, 2024
Est. expiryJun 29, 2036(~10 yrs left)· nominal 20-yr term from priority
A61K 31/4196A61K 31/437A61K 31/4427A61K 45/06C07D 249/00C07D 471/04A61P 19/02A61P 25/00A61P 29/00A61P 35/00A61P 37/00A61P 37/02A61P 43/00
91
PatentIndex Score
1
Cited by
62
References
17
Claims

Abstract

Disclosed are compounds of Formula (I) or a salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Claims

exact text as granted — not AI-modified
The invention claimed is: 
     
       1. A compound of Formula (I) 
       
         
           
           
               
               
           
         
         or a salt thereof, wherein: 
         R 1  is H, Cl, —CN, C 1-4  alkyl, C 1-3  fluoroalkyl, C 1-3  hydroxy-fluoroalkyl, —CR z ═CH 2 , C 3-6  cycloalkyl, —CH 2 (C 3-6  cycloalkyl), —C(O)O(C 1-3  alkyl), or tetrahydropyranyl; 
         each R 2  is independently halo, —CN, —OH, —NO 2   + , C 1-3  alkyl, C 1-2  fluoroalkyl, C 1-2  cyanoalkyl, C 1-3  hydroxyalkyl, C 1-3  aminoalkyl, —O(CH 2 ) 1-2 OH, —(CH 2 ) 0-4 O(C 1-4  alkyl), C 1-3  fluoroalkoxy, —(CH 2 ) 1-4 O(C 1-3  alkyl), —O(CH 2 ) 1-2 OC(O)(C 1-3  alkyl), —O(CH 2 ) 1-2 NR x R x , —C(O)O(C 1-3  alkyl), —C(O)NR y R y , —NR y R y , —NR y (C 1-3  fluoroalkyl), —NR y (C 1-4  hydroxyalkyl), —NR x CH 2 (phenyl), —NR x S(O) 2 (C 3-6  cycloalkyl), —NR x C(O)(C 1-3  alkyl), —NR x (CH 2 -cyclopropyl), C 3-6  cycloalkyl, morpholinyl, dioxothiomorpholinyl, methylpiperidinyl, methylpiperazinyl, amino-oxadiazolyl, imidazolyl, triazolyl, or —C(O)(thiazolyl); 
         R 3  is -L 1 -A; 
         L 1  is bond; 
         A is 2-oxa-6-azaspiro[3,3]heptanyl, 4-oxaspiro[2.5]octanyl, 7-azaspiro[3.5]nonanyl, 8-azabicyclo[3.2.1]octanyl, 8-oxa-3-azabicyclo[3.2.1]octanyl, 9-azabicyclo[3.3.1]nonanyl, adamantanyl, azepanyl, azetidinyl, C 3-6  cycloalkyl, diazepanyl, dihydroinonyl, dihydropyrimidinonyl, dioxanyl, dioxidothiadiazinanyl, dioxidothiazolidinyl, dioxidothiomorpholinyl, dioxoisothiazolidinyl, dioxidothiazinanyl, dioxotetrahydrothiophenyl, dioxotetrahydrothiopyranyl, dioxothiomorpholinyl, furanyl, imidazolyl, imidazolidinonyl, indolyl, isoquinolinyl, isoxazolyl, morpholinyl, morpholinonyl, naphthalenyl, octahydrocyclopenta[b]pyranyl, octahydropyrrolo[3,4-b]pyridinyl, oxazolidinonyl, oxadiazolyl, oxazolyl, oxetanyl, phenyl, piperidinyl, piperidinonyl, piperazinyl, piperazinonyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridazinonyl, pyridinonyl, pyridinyl, pyrimidinyl, pyrrolidinonyl, pyrrolidinyl, pyrrolyl, quinolinyl, quinolizinonyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrazolyl, thiadiazolyl, thiazolyl, triazolonyl, or triazolyl, each substituted with -L 2 -R a  and zero to 4 R b ; 
         L 2  is a bond or —CR x R x —; 
         R a  is:
 (a) H, F, Cl, —CN, —OH, C 1-6  alkyl, C 1-3  fluoroalkyl, C 1-5  hydroxyalkyl, —(CH 2 ) 0-4 O(C 1-3  alkyl), —(CR x R x ) 1-3 S(C 1-3  alkyl), —NHC(O)OC(CH 3 ) 3 , —(CR x R x ) 1-3 NHC(O)O(C 1-4  alkyl), —(CR x R x ) 1-3 NR y R y , —(CR x R x ) 1-3 C(O)NR y R y , —O(C 1-3  fluoroalkyl), —S(O) 2 NR x R x , —O(CR x R x ) 1-3 NR x R x , —NHS(O) 2 (C 1-3  alkyl), —NR x R x , —NR x (C 1-4  alkyl), —NR x C(O)(C 1-4  alkyl), —(CR x R x ) 0-3 C(O)OH, —C(O)(C 1-5  alkyl), —C(O)(C 1-3  fluoroalkyl), —C(O)O(C 1-4  alkyl), —C(O)NH(C 1-3  cyanoalkyl), —C(O)NR y R y , —C(O)NR x CH 2 C(O)NR x R x , or —C(O)NR x CH 2 CH 2 NHC(O)(C 1-3  alkyl); 
 (b) C 3-6  cycloalkyl or —C(O)NH(C 3-6  cycloalkyl), wherein each cycloalkyl is substituted with zero to 2 substituents independently selected from —OH, C 1-3  alkyl, C 1-3  hydroxyalkyl, C 1-3  fluoroalkyl, and —C(O)O(C 1-3  alkyl); or 
 (c) A 1 , —CH 2 A 1 , —C(O)A 1 , —NR x A 1 , or —C(O)NR x A 1 , wherein A 1  is furanyl, imidazolyl, indolyl, isoxazolyl, morpholinyl, octahydropyrrolo[3,4-c]pyrrolyl, oxazolyl, oxetanyl, phenyl, piperazinonyl, piperazinyl, piperidinyl, pyrazinyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrrolidinonyl, pyrrolidinyl, pyrrolyl, tetrahydrofuranyl, tetrahydropyranyl, thiadiazolyl, thiazolyl, thiophenyl, or triazolyl, each substituted with zero to three substituents independently selected from —OH, C 1-3  alkyl, C 1-3  hydroxyalkyl, —C(O)(C 1-2  alkyl), —C(O)O(C 1-3  alkyl), —NR x R x , phenyl, trifluoromethyl-phenyl, —CH 2 (bromophenyl), and —CH 2 CH 2 (pyrrolidinyl); 
 
         each R b  is independently F, —OH, —CH 3 , —CF 3 , or —OCH 3 ; 
         each R x  is independently H or —CH 3 ; 
         each R y  is independently H or C 1-6  alkyl; 
         R z  is H, C 1-2  alkyl, or C 1-2  fluoroalkyl; 
         each R 4  is independently F, —OH, C 1-2  alkyl, or —OCH 3 ; or two R 4  attached to the same carbon atom form ═O; or wherein when m is at least 2, two R 4 , each attached to a different carbon atom adjacent to the nitrogen atom in the piperidinyl ring, can form a —CH 2 CH 2 — bridge; 
         each R 5  is independently F, Cl, —CN, C 1-2  alkyl, C 1-2  fluoroalkyl, or —OCH 3 ; 
         m is zero, 1, 2, 3, or 4; 
         n is zero, 1, or 2; and 
         p is zero, 1, 2, 3, or 4. 
       
     
     
       2. The compound according to  claim 1  or salt thereof, wherein:
 R 1  is H, Cl, —CN, C 1-4  alkyl, or C 1-2  fluoroalkyl; 
 each R 2  is independently F, Cl, —CN, —OH, C 1-3  alkyl, C 1-2  fluoroalkyl, C 1-2  cyanoalkyl, C 1-3  hydroxyalkyl, C 1-3  aminoalkyl, —O(CH 2 ) 1-2 OH, —O(C 1-4  alkyl), C 1-2  fluoroalkoxy, —(CH 2 ) 1-4 O(C 1-3  alkyl), —O(CH 2 ) 1-2 OC(O)(C 1-3  alkyl), —O(CH 2 ) 1-2 NR x R x , —C(O)O(C 1-3  alkyl), —C(O)NR y R y , —NR y R y , —NR y (C 1-3  fluoroalkyl), —NR y (C 1-4  hydroxyalkyl), —NR x CH 2 (phenyl), —NR x S(O) 2 (C 3-6  cycloalkyl), —NR x C(O)(C 1-3  alkyl), —NR x (CH 2 -cyclopropyl), C 3-6  cycloalkyl, morpholinyl, dioxothiomorpholinyl, methylpiperidinyl, methylpiperazinyl, amino-oxadiazolyl, imidazolyl, triazolyl, or —C(O)(thiazolyl); 
 A is azetidinyl, C 3-6  cycloalkyl, dioxotetrahydrothiopyranyl, dioxidothiadiazinanyl, dioxidothiomorpholinyl, furanyl, imidazolyl, isoquinolinyl, morpholinyl, oxazolyl, 2-oxa-6-azaspiro[3.3]heptanyl, octahydropyrrolo[3,4-b]pyridinyl, oxetanyl, phenyl, piperazinonyl, piperazinyl, piperidinyl, pyrazinyl, pyrazolyl, pyridinyl, pyrrolidinonyl, pyrrolidinyl, pyrrolyl, quinolinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrazolyl, thiadiazolyl, thiazolyl, or triazolyl, each substituted with -L 2 -R a  and zero to 4 R b ; 
 R a  is:
 (a) H, F, —CN, —OH, C 1-3  alkyl, C 1-2  fluoroalkyl, C 1-3  hydroxyalkyl, —(CH 2 ) 0-2 O(C 1-3  alkyl), —NHC(O)OC(CH 3 ) 3 , —(CR x R x ) 1-3 NHC(O)O(C 1-4  alkyl), —(CR x R x ) 1-3 NH 2 , —(CR x R x ) 1-3 NR x (C 1-4  alkyl), —O(C 1-2  fluoroalkyl), —S(O) 2 NR x R x , —NHS(O) 2 (C 1-3  alkyl), —NR x R x , —NR x (C 1-4  alkyl), —(CR x R x ) 1-2 C(O)OH, —C(O)OH, —C(O)(C 1-3  alkyl), —C(O)O(C 1-4  alkyl), —C(O)NR x (C 1-2  alkyl), —C(O)N(C 1-3  alkyl) 2 , —C(O)NR x CH 2 C(O)NR x R x , or —C(O)NR x CH 2 CH 2 NHC(O)(C 1-3  alkyl); 
 (b) C 3-6  cycloalkyl or —C(O)NH(C 3-6  cycloalkyl), wherein each cycloalkyl is substituted with zero to 2 substituents independently selected from —OH, C 1-3  alkyl, C 1-3  hydroxyalkyl, C 1-3  fluoroalkyl, and —C(O)O(C 1-3  alkyl); or 
 (c) A 1 , —CH 2 A 1 , —C(O)A 1 , or —C(O)NHA 1 , wherein A 1  is furanyl, imidazolyl, indolyl, isoxazolyl, octahydropyrrolo[3,4-c]pyrrolyl, oxazolyl, oxetanyl, phenyl, piperazinyl, piperidinyl, pyrazinyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, tetrahydrofuranyl, tetrahydropyranyl, thiadiazolyl, thiazolyl, thiophenyl, or triazolyl, each substituted with zero to three substituents independently selected from —OH, C 1-3  alkyl, C 1-3  hydroxyalkyl, —C(O)(C 1-2  alkyl), —C(O)O(C 1-3  alkyl), —NR x R x , phenyl, trifluoromethylphenyl, —CH 2 (bromophenyl), and —CH 2 CH 2 (pyrrolidinyl); 
 
 each R 4  is independently F, —OH, C 1-2  alkyl, or —OCH 3 ; or two R 4  attached to the same carbon atom form ═O; 
 R 5  is F, Cl, —CN, —CH 3 , —CF 3 , or —OCH 3 ; 
 each R b  is independently —OH, —CH 3 , or —CF 3 ; 
 each R x  is independently H or —CH 3 ; 
 each R y  is independently H or C 1-5  alkyl; 
 m is zero, 1, or 2; 
 n is zero or 1; and 
 p is zero, 1, or 2. 
 
     
     
       3. The compound according to  claim 1  or salt thereof, wherein:
 R 1  is —CH 2 CH 3 , —CH(CH 3 ) 2 , or —CH 2 CHF 2 ; 
 each R 2  is independently F, Cl, —CN, —CH 3 , —CD 3 , —CH 2 CH 3 , —CH(CH 3 ) 2 , —CF 3 , —CH 2 CN, —CH 2 OH, —CH 2 CH 2 OH, —CH(CH 3 )OH, —C(CH 3 ) 2 OH, —OCH 2 CH 2 OH, —OCH 3 , —OCH 2 CH 3 , —CH 2 OCH 3 , —OCH 2 CH 2 OC(O)CH 3 , —NH(CH 2 CF 3 ), —NHS(O) 2 (cyclopropyl), cyclopropyl, morpholinyl, dioxothiomorpholinyl, or methylpiperazinyl; 
 A is C 4-6  cycloalkyl, dioxanyl, dioxotetrahydrothiophenyl, dioxotetrahydrothiopyranyl, oxetanyl, pyridinyl, pyrimidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, or triazolyl, each substituted with -L 2 -R a  and zero to 1 R b ; 
 L 2  is a bond; 
 R a  is —CN, —OH, —CH 3 , —NHC(O)OC(CH 3 ) 3 , or —C(O)OCH 2 CH 3 ; 
 R b  is —CH 3 ; 
 m is zero; 
 n is zero; and 
 p is zero, 1 or 2. 
 
     
     
       4. The compound according to  claim 1  or salt thereof, wherein:
 R 1  is —CH 2 CH 3 , —CH(CH 3 ) 2 , or —CH 2 CHF 2 ; 
 A is oxetanyl, tetrahydrofuranyl, or tetrahydropyranyl, each substituted with -L 2 -R a  and zero to 2 R b ; 
 L 2  is a bond; 
 m is zero or 1; 
 n is zero; and 
 p is zero, 1 or 2. 
 
     
     
       5. The compound according to  claim 1  or salt thereof, wherein:
 R 1  is —CH 2 CH 3 , —CH(CH 3 ) 2 , or —CH 2 CHF 2 ; 
 A is cyclobutyl, cyclopentyl, or dioxotetrahydrothiopyranyl, each substituted with -L 2 -R a  and zero to 2 R b ; 
 L 2  is a bond; 
 m is zero or 1; 
 n is zero; and 
 p is zero, 1 or 2. 
 
     
     
       6. The compound according to  claim 1  or a salt thereof, wherein said compound is:
 4-(4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-indol-5-yl)piperidin-1-yl)tetrahydro-2H-thiopyran 1,1-dioxide (20); 
 6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (26); 
 6-(3-isopropyl-5-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-indol-2-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (35); 
 4-(4-(3-isopropyl-2-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-indol-5-yl)piperidin-1-yl)tetrahydro-2H-thiopyran 1,1-dioxide (37); 
 6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (38); 
 6-(3-isopropyl-5-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-indol-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (40); 
 6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (44); 
 6-(3-isopropyl-5-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-indol-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (45); 
 3-(4-(2-(8-(hydroxymethyl)-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-indol-5-yl)piperidin-1-yl)oxetane-3-carbonitrile (235); 
 6-(3-isopropyl-5-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-indol-2-yl)-[1,2,4]triazolo[1,5-a]pyridine (351); 
 6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-[1,2,4]triazolo[1,5-a]pyridine (352); 
 6-(3-isopropyl-5-(1-((1-methyl-1H-1,2,4-triazol-3-yl)methyl)piperidin-4-yl)-1H-indol-2-yl)-[1,2,4]triazolo[1,5-a]pyridine (353); 
 6-(3-isopropyl-5-(1-(tetrahydro-2H-pyran-3-yl)piperidin-4-yl)-1H-indol-2-yl)-[1,2,4]triazolo[1,5-a]pyridine (354); 
 6-(3-isopropyl-5-(1-(tetrahydrofuran-3-yl)piperidin-4-yl)-1H-indol-2-yl)-[1,2,4]triazolo[1,5-a]pyridine (355); 
 6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-8-(trideuteromethyl)-[1,2,4]triazolo[1,5-a]pyridine (357); 
 6-(3-isopropyl-5-(1-(tetrahydrofuran-3-yl)piperidin-4-yl)-1H-indol-2-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (393); 
 6-(3-isopropyl-5-(1-(tetrahydro-2H-pyran-3-yl)piperidin-4-yl)-1H-indol-2-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (394); 
 3-(4-(3-isopropyl-2-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-indol-5-yl)piperidin-1-yl)tetrahydrothiophene 1,1-dioxide (395); 
 4-(4-(3-isopropyl-2-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-indol-5-yl)piperidin-1-yl)cyclohexan-1-ol (403); 
 2-(4-(3-isopropyl-2-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-indol-5-yl)piperidin-1-yl)-1-methylcyclopentane-1-carbonitrile (416-417); 
 6-(3-isopropyl-5-(1-(tetrahydro-2H-thiopyran-4-yl)piperidin-4-yl)-1H-indol-2-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (425); 
 6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-7-methyl-[1,2,4]triazolo[1,5-a]pyridine (441); 
 6-(3-isopropyl-5-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-indol-2-yl)-7-methyl-[1,2,4]triazolo[1,5-a]pyridine (443); 
 3-(4-(3-isopropyl-2-(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-indol-5-yl)piperidin-1-yl)tetrahydrothiophene 1,1-dioxide (460); 
 8-fluoro-6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-[1,2,4]triazolo[1,5-a]pyridine (469); 
 6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-8-(methoxymethyl)-[1,2,4]triazolo[1,5-a]pyridine (473); 
 6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (487); 
 6-(3-isopropyl-5-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-indol-2-yl)-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (488); 
 4-(4-(2-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-indol-5-yl)piperidin-1-yl)tetrahydro-2H-thiopyran 1,1-dioxide (489); 
 2-(6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)propan-2-ol (492); 
 2-(6-(3-isopropyl-5-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-indol-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)propan-2-ol (493); 
 4-(4-(2-(8-(2-hydroxypropan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-indol-5-yl)piperidin-1-yl)tetrahydro-2H-thiopyran 1,1-dioxide (496); 
 6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-8-(methoxymethyl)-7-methyl-[1,2,4]triazolo[1,5-a]pyridine (499); 
 6-(3-isopropyl-5-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-indol-2-yl)-[1,2,4]triazolo[1,5-a]pyridine-8-carbonitrile (500); 
 6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-[1,2,4]triazolo[1,5-a]pyridine-8-carbonitrile (501); 
 1-(6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)ethan-1-ol (503); 
 (6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-7-methyl-[1,2,4]triazolo[1,5-a]pyridin-8-yl)methanol (504); 
 2-(6-(3-isopropyl-5-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-indol-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)acetonitrile (506); 
 8-fluoro-6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-7-methyl-[1,2,4]triazolo[1,5-a]pyridine (507); 
 (6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl)methanol (508); 
 (6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)methanol (510); 
 4-(4-(2-(8-(hydroxymethyl)-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-indol-5-yl)piperidin-1-yl)tetrahydro-2H-thiopyran 1,1-dioxide (514); 
 (6-(3-isopropyl-5-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-indol-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)methanol (521); 
 2-(6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)ethan-1-ol (525); 
 2-((6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)oxy)ethyl acetate (528); 
 2-((6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)oxy)ethan-1-ol (529-530); 
 6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-2-methyl-[1,2,4]triazolo[1,5-a]pyridine (534); 
 6-(3-isopropyl-5-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-indol-2-yl)-2-methyl-[1,2,4]triazolo[1,5-a]pyridine (535); 
 tert-butyl (3-(4-(3-isopropyl-2-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-indol-5-yl)piperidin-1-yl)cyclobutyl)carbamate (538); 
 ethyl 3-(4-(3-isopropyl-2-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-indol-5-yl)piperidin-1-yl)cyclobutane-1-carboxylate (539); 
 6-(3-isopropyl-5-(1-(tetrahydrofuran-3-yl)piperidin-4-yl)-1H-indol-2-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (540-541); 
 6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-2,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (542); 
 6-(3-isopropyl-5-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-indol-2-yl)-2,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (543); 
 4-(4-(2-(2,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-indol-5-yl)piperidin-1-yl)tetrahydro-2H-thiopyran 1,1-dioxide (545); 
 6-(3-isopropyl-5-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-indol-2-yl)-2,7-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (546); 
 6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-2,7-dimethyl-[1,2,4]triazolo [1,5-a]pyridine (547); 
 4-(4-(2-(2,7-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-indol-5-yl)piperidin-1-yl)tetrahydro-2H-thiopyran 1,1-dioxide (548); 
 6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-8-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine (549); 
 4-(4-(3-isopropyl-2-(8-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-indol-5-yl)piperidin-1-yl)tetrahydro-2H-thiopyran 1,1-ioxide (550); 
 6-(3-isopropyl-5-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-indol-2-yl)-8-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine (552); 
 6-(3-isopropyl-5-(1-(tetrahydro-2H-pyran-3-yl)piperidin-4-yl)-1H-indol-2-yl)-8-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine (554); 
 4-(4-(3-isopropyl-2-(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-indol-5-yl)piperidin-1-yl)tetrahydro-2H-thiopyran 1,1-dioxide (455); 
 6-(3-isopropyl-5-(1-(tetrahydrofuran-3-yl)piperidin-4-yl)-1H-indol-2-yl)-8-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine (556-557); 
 6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-2,5-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (558); 
 4-(4-(3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-indol-5-yl)piperidin-1-yl)tetrahydro-2H-thiopyran 1,1-dioxide (561); 
 6-(5-(1-(2,2-dimethyltetrahydro-2H-pyran-4-yl)piperidin-4-yl)-3-isopropyl-1H-indol-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (562-564); 
 3-(4-(3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-indol-5-yl)piperidin-1-yl)cyclobutane-1-carbonitrile (567); 
 6-(3-isopropyl-5-(1-(tetrahydrofuran-3-yl)piperidin-4-yl)-1H-indol-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (568-569); 
 8-ethoxy-6-(3-isopropyl-5-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-indol-2-yl)-[1,2,4]triazolo[1,5-a]pyridine (571); 
 8-ethoxy-6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-[1,2,4]triazolo[1,5-a]pyridine (572); 
 4-(4-(2-(8-ethoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-indol-5-yl)piperidin-1-yl)tetrahydro-2H-thiopyran 1,1-dioxide (573); 
 6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-8-methoxy-2-methyl-[1,2,4]triazolo[1,5-a]pyridine (574); 
 6-(3-isopropyl-5-(1-(tetrahydrofuran-3-yl)piperidin-4-yl)-1H-indol-2-yl)-8-methoxy-2-methyl-[1,2,4]triazolo[1,5-a]pyridine (575-576); 
 8-ethyl-6-(3-isopropyl-5-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-indol-2-yl)-2-methyl-[1,2,4]triazolo[1,5-a]pyridine (577); 
 8-ethyl-6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-2-methyl-[1,2,4]triazolo[1,5-a]pyridine (578); 
 8-chloro-6-(3-isopropyl-5-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-indol-2-yl)-7-methyl-[1,2,4]triazolo[1,5-a]pyridine (579); 
 8-chloro-6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-7-methyl-[1,2,4]triazolo[1,5-a]pyridine (580); 
 4-(6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)morpholine (581); 
 8-ethyl-6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-[1,2,4]triazolo[1,5-a]pyridine (583); 
 8-isopropyl-6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-[1,2,4]triazolo[1,5-a]pyridine (585); 
 6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-N-(2,2,2-trifluoroethyl)-[1,2,4]triazolo[1,5-a]pyridin-8-amine (586); 
 8-ethyl-6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-7-methyl-[1,2,4]triazolo[1,5-a]pyridine (587); 
 6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-8-methoxy-7-methyl-[1,2,4]triazolo[1,5-a]pyridine (588); 
 N-(6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)cyclopropanesulfonamide (590); 
 4-(6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)thiomorpholine 1,1-dioxide (591); 
 6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-8-(4-methylpiperazin-1-yl)-[1,2,4]triazolo[1,5-a]pyridine (592); 
 8-cyclopropyl-6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-[1,2,4]triazolo[1,5-a]pyridine (593); 
 8-cyclopropyl-6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-2-methyl-[1,2,4]triazolo[1,5-a]pyridine (594); 
 8-cyclopropyl-6-(3-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-7-methyl-[1,2,4]triazolo[1,5-a]pyridine (595); 
 6-(3-ethyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (596); 
 6-(3-(2,2-difluoroethyl)-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (597); 
 6-(3-(2,2-difluoroethyl)-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (598); 
 6-(3-ethyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indol-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (600); 
 6-(3-isopropyl-5-(1-(pyridin-2-yl)piperidin-4-yl)-1H-indol-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (986); 
 6-(3-isopropyl-5-(1-(pyrimidin-2-yl)piperidin-4-yl)-1H-indol-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (989); or 
 6-(5-(1-(2,2-dimethyl-1,3-dioxan-5-yl)piperidin-4-yl)-4-fluoro-3-isopropyl-1H-indol-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (993). 
 
     
     
       7. The compound according to  claim 1  or a salt thereof, wherein said compound is: 
       
         
           
           
               
               
           
         
       
     
     
       8. The compound according to  claim 1  or a salt thereof, wherein said compound is: 
       
         
           
           
               
               
           
         
       
     
     
       9. The compound according to  claim 1  or a salt thereof, wherein said compound is: 
       
         
           
           
               
               
           
         
       
     
     
       10. A pharmaceutical composition comprising a compound according to  claim 1  or a pharmaceutically-acceptable salt thereof; and a pharmaceutically acceptable carrier. 
     
     
       11. A pharmaceutical composition comprising a compound according to  claim 7  or a pharmaceutically-acceptable salt thereof; and a pharmaceutically acceptable carrier. 
     
     
       12. A pharmaceutical composition comprising a compound according to  claim 8  or a pharmaceutically-acceptable salt thereof; and a pharmaceutically acceptable carrier. 
     
     
       13. A pharmaceutical composition comprising a compound according to  claim 9  or a pharmaceutically-acceptable salt thereof; and a pharmaceutically acceptable carrier. 
     
     
       14. A method of treating an autoimmune disease or a chronic inflammatory disease, comprising administering to a mammalian patent patient a compound according to  claim 1  or a pharmaceutically acceptable salt thereof, wherein said autoimmune disease or chronic inflammatory disease is systemic lupus erythematosus. 
     
     
       15. A method of treating an autoimmune disease or a chronic inflammatory disease, comprising administering to a mammalian patent patient a compound according to  claim 7  or a pharmaceutically acceptable salt thereof, wherein said autoimmune disease or chronic inflammatory disease is systemic lupus erythematosus. 
     
     
       16. A method of treating an autoimmune disease or a chronic inflammatory disease, comprising administering to a mammalian patent patient a compound according to  claim 8  or a pharmaceutically acceptable salt thereof, wherein said autoimmune disease or chronic inflammatory disease is systemic lupus erythematosus. 
     
     
       17. A method of treating an autoimmune disease or a chronic inflammatory disease, comprising administering to a mammalian patent patient a compound according to  claim 9  or a pharmaceutically acceptable salt thereof, wherein said autoimmune disease or chronic inflammatory disease is systemic lupus erythematosus.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.